TY - JOUR
T1 - Genome-wide association study of eosinophilic granulomatosis with polyangiitis reveals genomic loci stratified by ANCA status
AU - The European Vasculitis Genetics Consortium
AU - Lyons, Paul A.
AU - Peters, James E.
AU - Alberici, Federico
AU - Liley, James
AU - Coulson, Richard M.R.
AU - Astle, William
AU - Baldini, Chiara
AU - Bonatti, Francesco
AU - Cid, Maria C.
AU - Elding, Heather
AU - Emmi, Giacomo
AU - Epplen, Jörg
AU - Guillevin, Loïc
AU - Jayne, David R.W.
AU - Jiang, Tao
AU - Gunnarsson, Iva
AU - Lamprecht, Peter
AU - Leslie, Stephen
AU - Little, Mark A.
AU - Martorana, Davide
AU - Moosig, Frank
AU - Neumann, Thomas
AU - Ohlsson, Sophie
AU - Quickert, Stefanie
AU - Ramirez, Giuseppe A.
AU - Rewerska, Barbara
AU - Schett, Georg
AU - Sinico, Renato A.
AU - Szczeklik, Wojciech
AU - Tesar, Vladimir
AU - Vukcevic, Damjan
AU - Akil, Mohammed
AU - Barratt, Jonathan
AU - Basu, Neil
AU - Butterworth, Adam S.
AU - Bruce, Ian
AU - Clarkson, Michael
AU - Conlon, Niall
AU - DasGupta, Bhaskar
AU - Doulton, Timothy W.R.
AU - Espígol-Frigolé, Georgina
AU - Flossmann, Oliver
AU - Gabrielli, Armando
AU - Gasior, Jolanta
AU - Gregorini, Gina
AU - Guida, Giuseppe
AU - Hernández-Rodríguez, José
AU - Hruskova, Zdenka
AU - Hudson, Amy
AU - Holle, Julia U.
N1 - Funding Information:
This work was funded primarily by Project Grants from Arthritis Research UK (20593 to Drs. Smith and Lyons) and the British Heart Foundation (PG/13/64/30435 to Drs. Smith and Lyons). Additional support was provided by the NIHR Cambridge Biomedical Research Centre, the West Anglia Comprehensive Research Network, a Medical Research Council Programme Grant (MR/L019027/1 to Dr. Smith), a Wellcome Trust Investigator Award (200871/Z/16/Z to Dr. Smith), a NIHR Senior Investigator Award (to Dr. Smith), a Wellcome Trust Senior Research Fellowship (WT107881 to Dr. Wallace), a Medical Research Council grant (MC_UU_00002/4 to Dr. Wallace), a Wellcome Trust Mathematical Genomics and Medicine Programme Studentship (to Dr. Liley), a Career Development Award from the Cambridge British Heart Foundation Centre for Research Excellence and a UK Research Innovation Fellowship (RE/13/6/30180 and MR/S004068/ 1 to Dr. Peters). Additional aspects of this work were supported by the following funding: a Science Foundation Ireland Grant (11/Y/B2093 to Dr Little); an Australian National Health and Medical Research Council (NH&MRC), Career Development Fellowship (ID 1053756) and a Victorian Life Sciences Computation Initiative (VLSCI) grant number (VR0240) on its Peak Computing Facility at the University of Melbourne, an initiative of the Victorian Government, Australia (to Dr Leslie); Research at the Murdoch Children’s Research Institute was supported by the Victorian Government’s Operational Infrastructure Support Program; Project RVO 64 165 of the Ministry of Health of Czech Republic (to Dr Tesar); Ministerio de Economía y Competitividad (SAF SAF 2017-88275-R), FEDER una manera de hacer Europa) and CERCA programme (to Drs Cid and Hernández-Rodríguez) and Instituto de Salud Carlos III (PI 18/00461) (to Drs Espígol-Frigolé and Prieto-Gonzalez); Prof Bruce is an NIHR Senior Investigator and is supported by Versus Arthritis, the National Institute for Health Research Manchester Biomedical Research Centre and the NIHR Manchester Clinical Research Facility. We thank the Centre for Integrated Genomic Medical Research Biobank for sample storage and preparation, and AROS Applied Biotechnology (Aarhus, Denmark) and Cambridge Genomic Services (Cambridge, UK) for genotyping.
Publisher Copyright:
© 2019, The Author(s).
Copyright:
Copyright 2020 Elsevier B.V., All rights reserved.
PY - 2019/12/1
Y1 - 2019/12/1
N2 - Eosinophilic granulomatosis with polyangiitis (EGPA) is a rare inflammatory disease of unknown cause. 30% of patients have anti-neutrophil cytoplasmic antibodies (ANCA) specific for myeloperoxidase (MPO). Here, we describe a genome-wide association study in 676 EGPA cases and 6809 controls, that identifies 4 EGPA-associated loci through conventional case-control analysis, and 4 additional associations through a conditional false discovery rate approach. Many variants are also associated with asthma and six are associated with eosinophil count in the general population. Through Mendelian randomisation, we show that a primary tendency to eosinophilia contributes to EGPA susceptibility. Stratification by ANCA reveals that EGPA comprises two genetically and clinically distinct syndromes. MPO+ ANCA EGPA is an eosinophilic autoimmune disease sharing certain clinical features and an HLA-DQ association with MPO+ ANCA-associated vasculitis, while ANCA-negative EGPA may instead have a mucosal/barrier dysfunction origin. Four candidate genes are targets of therapies in development, supporting their exploration in EGPA.
AB - Eosinophilic granulomatosis with polyangiitis (EGPA) is a rare inflammatory disease of unknown cause. 30% of patients have anti-neutrophil cytoplasmic antibodies (ANCA) specific for myeloperoxidase (MPO). Here, we describe a genome-wide association study in 676 EGPA cases and 6809 controls, that identifies 4 EGPA-associated loci through conventional case-control analysis, and 4 additional associations through a conditional false discovery rate approach. Many variants are also associated with asthma and six are associated with eosinophil count in the general population. Through Mendelian randomisation, we show that a primary tendency to eosinophilia contributes to EGPA susceptibility. Stratification by ANCA reveals that EGPA comprises two genetically and clinically distinct syndromes. MPO+ ANCA EGPA is an eosinophilic autoimmune disease sharing certain clinical features and an HLA-DQ association with MPO+ ANCA-associated vasculitis, while ANCA-negative EGPA may instead have a mucosal/barrier dysfunction origin. Four candidate genes are targets of therapies in development, supporting their exploration in EGPA.
UR - http://www.scopus.com/inward/record.url?scp=85074947375&partnerID=8YFLogxK
U2 - 10.1038/s41467-019-12515-9
DO - 10.1038/s41467-019-12515-9
M3 - Journal articles
C2 - 31719529
AN - SCOPUS:85074947375
SN - 1751-8628
VL - 10
JO - Nature Communications
JF - Nature Communications
IS - 1
M1 - 5120
ER -